Hi friends 👋🏼,

I finally got a PS5 and dived right into playing the latest Star Wars game! As I zipped through those awesome galaxies, it hit me how puzzling and intricate the game is - kind of like clinical trials. So, I hit the pause button on gaming and wrote Clinical Trials 101 to help you unravel the twists and turns of clinical trials without the jargon.

How’d you like my transition from Star Wars to clinical trials. Corny, I’m sure 😂

Either way, we’ve got a brand new approval for you this week, plus more cool science:

• First Drug Ever for Friedreich’s Ataxia Approved ^{READER REQUEST}

• Promising New Treatment for Hidradenitis Suppurativa ^{READER REQUEST}

• New Clinical Data for Sickle Cell CRISPR Therapy ^{READER REQUEST}

• Combating Polycythemia Vera ^{READER REQUEST}

🎊 First Drug for Friedreich’s Ataxia Approved

Friedreich’s ataxia (FA) is a debilitating neurological disease that progressively damages the brain, nervous system, and muscles, leading to severe impairments. Until now, there were no approved treatments, and severe patients had a life expectancy in the mid-30s.

February, 2023 marked a historic month for the patient community as the first drug to fight FA was approved! 👇🏼

Subscribe to Premium to read the rest.